A Special Message from Robert Best, Executive Vice President, CDS Pacific
“On behalf of the CDS Pacific team, I am delighted to announce the launch of MIMS Drugs4dent® for the Australian market – this is a new, medicines resource to target dental practitioners and Oral Health specialists which was developed in conjunction with leading Oral Health Australian academics from the University of Melbourne, Dr Leanne Teoh and Professor Michael McCullough.
Dr Teoh realised that drug resources were lacking in the dental industry to assist dentists on the impact of drugs on dental treatment, prescribing guidance and clinical tools to assist with dose calculations and safe prescribing. Professor McCullough, Professor of Oral Medicine at the Melbourne Dental School with a long-standing interest in dental prescribing, also noted a lack of a resource for dentists that included all aspects of medications encountered in dental practice that would enhance dentists’ knowledge of medications and their potential unwanted side-effects. This is not only for the medications that they prescribe, but the medications our patients are taking, which are increasing in both number and complexity.
With drug information constantly evolving, MIMS Drugs4dent® provides up-to-date dental-relevant information on prescription drugs, over-the-counter products and complementary medicines, so dental practitioners will be alerted to the impacts that drugs can have on dental procedures. MIMS Drugs4dent® provides clinical decision support to improve medication safety by including drug and allergy interactions, pregnancy and lactation recommendations, and paediatric dosing guidance for dental indications.
MIMS Drugs4dent® is the first Australian medicines information resource designed specifically for dental practitioners. It provides succinct, dental-relevant information for practitioners in clinical settings to understand the effect of medications on dental treatment and support clinicians to accurately and safely prescribe. This clinical decision tool should allow for safe dental prescribing of both systemic and topical medications.
Continuing with our 60-year history being a leading provider of medicines knowledge and information, accessing a new dental market in 2024 is an exciting time for the MIMS Australia / CDS Pacific team.”